APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pembrolizumab

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pembrolizumab Market Outlook and Growth Opportunities 2026

23 December 2025194 pages

Choose your research edition.

Industry ResearchPembrolizumab Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Pembrolizumab Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Pembrolizumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pembrolizumab Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pembrolizumab Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Pembrolizumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pembrolizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pembrolizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pembrolizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pembrolizumab market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pembrolizumab market include Merck. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pembrolizumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pembrolizumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pembrolizumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pembrolizumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Pembrolizumab Segment by Company

Merck

Pembrolizumab Segment by Type

50mg Injection

100mg Injection

Pembrolizumab Segment by Application

Unresectable or Metastatic Solid Tumor

Advanced Melanoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

Others

Pembrolizumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pembrolizumab status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pembrolizumab market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pembrolizumab significant trends, drivers, influence factors in global and regions.

6. To analyze Pembrolizumab competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pembrolizumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pembrolizumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pembrolizumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pembrolizumab market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pembrolizumab industry.

Chapter 3: Detailed analysis of Pembrolizumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pembrolizumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pembrolizumab in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pembrolizumab Industry Trends Table 2. Pembrolizumab Industry Drivers Table 3. Pembrolizumab Industry Opportunities and Challenges Table 4. Pembrolizumab Industry Restraints Table 5. Global Pembrolizumab Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pembrolizumab Revenue Share by Company (2021-2026) Table 7. Global Pembrolizumab Sales Volume by Company (k pcs) & (2021-2026) Table 8. Global Pembrolizumab Sales Volume Share by Company (2021-2026) Table 9. Global Pembrolizumab Average Price (US$/pcs) of Company (2021-2026) Table 10. Global Pembrolizumab Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pembrolizumab Key Company Manufacturing Base & Headquarters Table 12. Global Pembrolizumab Company, Product Type & Application Table 13. Global Pembrolizumab Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pembrolizumab by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 50mg Injection Table 18. Significant Companies of 100mg Injection Table 19. Global Pembrolizumab Sales Volume by Type 2021 VS 2025 VS 2032 (k pcs) Table 20. Global Pembrolizumab Sales Volume by Type (2021-2026) & (k pcs) Table 21. Global Pembrolizumab Sales Volume by Type (2027-2032) & (k pcs) Table 22. Global Pembrolizumab Sales Volume Share by Type (2021-2026) Table 23. Global Pembrolizumab Sales Volume Share by Type (2027-2032) Table 24. Global Pembrolizumab Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pembrolizumab Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Pembrolizumab Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Pembrolizumab Sales Value Share by Type (2021-2026) Table 28. Global Pembrolizumab Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Unresectable or Metastatic Solid Tumor Table 30. Significant Companies of Advanced Melanoma Table 31. Significant Companies of Head and Neck Squamous Cell Carcinoma (HNSCC) Table 32. Significant Companies of Others Table 33. Global Pembrolizumab Sales Volume by Application 2021 VS 2025 VS 2032 (k pcs) Table 34. Global Pembrolizumab Sales Volume by Application (2021-2026) & (k pcs) Table 35. Global Pembrolizumab Sales Volume by Application (2027-2032) & (k pcs) Table 36. Global Pembrolizumab Sales Volume Share by Application (2021-2026) Table 37. Global Pembrolizumab Sales Volume Share by Application (2027-2032) Table 38. Global Pembrolizumab Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Pembrolizumab Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Pembrolizumab Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Pembrolizumab Sales Value Share by Application (2021-2026) Table 42. Global Pembrolizumab Sales Value Share by Application (2027-2032) Table 43. Global Pembrolizumab Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 44. Global Pembrolizumab Sales by Region (2021-2026) & (k pcs) Table 45. Global Pembrolizumab Sales Market Share by Region (2021-2026) Table 46. Global Pembrolizumab Sales by Region (2027-2032) & (k pcs) Table 47. Global Pembrolizumab Sales Market Share by Region (2027-2032) Table 48. Global Pembrolizumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Pembrolizumab Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Pembrolizumab Sales Value Share by Region (2021-2026) Table 51. Global Pembrolizumab Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Pembrolizumab Sales Value Share by Region (2027-2032) Table 53. Global Pembrolizumab Market Average Price (US$/pcs) by Region (2021-2026) Table 54. Global Pembrolizumab Market Average Price (US$/pcs) by Region (2027-2032) Table 55. Global Pembrolizumab Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Table 56. Global Pembrolizumab Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Pembrolizumab Sales by Country (2021-2026) & (k pcs) Table 58. Global Pembrolizumab Sales Market Share by Country (2021-2026) Table 59. Global Pembrolizumab Sales by Country (2027-2032) & (k pcs) Table 60. Global Pembrolizumab Sales Market Share by Country (2027-2032) Table 61. Global Pembrolizumab Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Pembrolizumab Sales Value Market Share by Country (2021-2026) Table 63. Global Pembrolizumab Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Pembrolizumab Sales Value Market Share by Country (2027-2032) Table 65. Merck Company Information Table 66. Merck Business Overview Table 67. Merck Pembrolizumab Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 68. Merck Pembrolizumab Product Portfolio Table 69. Merck Recent Development Table 70. Key Raw Materials Table 71. Raw Materials Key Suppliers Table 72. Pembrolizumab Distributors List Table 73. Pembrolizumab Customers List Table 74. Research Programs/Design for This Report Table 75. Authors List of This Report Table 76. Secondary Sources Table 77. Primary Sources List of Figures Figure 1. Pembrolizumab Product Image Figure 2. Global Pembrolizumab Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pembrolizumab Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pembrolizumab Sales (2021-2032) & (k pcs) Figure 5. Global Pembrolizumab Sales Average Price (US$/pcs) & (2021-2032) Figure 6. Global Pembrolizumab Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 50mg Injection Image Figure 10. 100mg Injection Image Figure 11. Global Pembrolizumab Sales Volume by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 12. Global Pembrolizumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Pembrolizumab Sales Volume Share by Type (2021-2032) Figure 14. Global Pembrolizumab Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pembrolizumab Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pembrolizumab Sales Value Share by Type (2021-2032) Figure 17. Unresectable or Metastatic Solid Tumor Image Figure 18. Advanced Melanoma Image Figure 19. Head and Neck Squamous Cell Carcinoma (HNSCC) Image Figure 20. Others Image Figure 21. Global Pembrolizumab Sales Volume by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 22. Global Pembrolizumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Pembrolizumab Sales Volume Share by Application (2021-2032) Figure 24. Global Pembrolizumab Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Pembrolizumab Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Pembrolizumab Sales Value Share by Application (2021-2032) Figure 27. Global Pembrolizumab Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 28. Global Pembrolizumab Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Pembrolizumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Pembrolizumab Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Pembrolizumab Sales Value (2021-2032) & (US$ Million) Figure 32. North America Pembrolizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Pembrolizumab Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Pembrolizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Pembrolizumab Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Pembrolizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Pembrolizumab Sales Value (2021-2032) & (US$ Million) Figure 38. South America Pembrolizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Pembrolizumab Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Pembrolizumab Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Pembrolizumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Pembrolizumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Pembrolizumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Pembrolizumab Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Pembrolizumab Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 50mg Injection
  • 100mg Injection
Applications
  • Unresectable or Metastatic Solid Tumor
  • Advanced Melanoma
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Others
Companies covered
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pembrolizumab Sales Value (2021-2032)
  4. 1.2.2 Global Pembrolizumab Sales Volume (2021-2032)
  5. 1.2.3 Global Pembrolizumab Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pembrolizumab Market Dynamics
  1. 2.1 Pembrolizumab Industry Trends
  2. 2.2 Pembrolizumab Industry Drivers
  3. 2.3 Pembrolizumab Industry Opportunities and Challenges
  4. 2.4 Pembrolizumab Industry Restraints
3 Pembrolizumab Market by Company
  1. 3.1 Global Pembrolizumab Company Revenue Ranking in 2025
  2. 3.2 Global Pembrolizumab Revenue by Company (2021-2026)
  3. 3.3 Global Pembrolizumab Sales Volume by Company (2021-2026)
  4. 3.4 Global Pembrolizumab Average Price by Company (2021-2026)
  5. 3.5 Global Pembrolizumab Company Ranking (2024-2026)
  6. 3.6 Global Pembrolizumab Company Manufacturing Base and Headquarters
  7. 3.7 Global Pembrolizumab Company Product Type and Application
  8. 3.8 Global Pembrolizumab Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pembrolizumab Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pembrolizumab Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pembrolizumab Market by Type
  1. 4.1 Pembrolizumab Type Introduction
  2. 4.1.1 50mg Injection
  3. 4.1.2 100mg Injection
  4. 4.2 Global Pembrolizumab Sales Volume by Type
  5. 4.2.1 Global Pembrolizumab Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pembrolizumab Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Pembrolizumab Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Pembrolizumab Sales Value by Type
  9. 4.3.1 Global Pembrolizumab Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pembrolizumab Sales Value by Type (2021-2032)
  11. 4.3.3 Global Pembrolizumab Sales Value Share by Type (2021-2032)
5 Pembrolizumab Market by Application
  1. 5.1 Pembrolizumab Application Introduction
  2. 5.1.1 Unresectable or Metastatic Solid Tumor
  3. 5.1.2 Advanced Melanoma
  4. 5.1.3 Head and Neck Squamous Cell Carcinoma (HNSCC)
  5. 5.1.4 Others
  6. 5.2 Global Pembrolizumab Sales Volume by Application
  7. 5.2.1 Global Pembrolizumab Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Pembrolizumab Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Pembrolizumab Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Pembrolizumab Sales Value by Application
  11. 5.3.1 Global Pembrolizumab Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Pembrolizumab Sales Value by Application (2021-2032)
  13. 5.3.3 Global Pembrolizumab Sales Value Share by Application (2021-2032)
6 Pembrolizumab Regional Sales and Value Analysis
  1. 6.1 Global Pembrolizumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pembrolizumab Sales by Region (2021-2032)
  3. 6.2.1 Global Pembrolizumab Sales by Region: 2021-2026
  4. 6.2.2 Global Pembrolizumab Sales by Region (2027-2032)
  5. 6.3 Global Pembrolizumab Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pembrolizumab Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pembrolizumab Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pembrolizumab Sales Value by Region (2027-2032)
  9. 6.5 Global Pembrolizumab Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pembrolizumab Sales Value (2021-2032)
  12. 6.6.2 North America Pembrolizumab Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pembrolizumab Sales Value (2021-2032)
  15. 6.7.2 Europe Pembrolizumab Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pembrolizumab Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pembrolizumab Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pembrolizumab Sales Value (2021-2032)
  21. 6.9.2 South America Pembrolizumab Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pembrolizumab Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pembrolizumab Sales Value Share by Country, 2025 VS 2032
7 Pembrolizumab Country-level Sales and Value Analysis
  1. 7.1 Global Pembrolizumab Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pembrolizumab Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pembrolizumab Sales by Country (2021-2032)
  4. 7.3.1 Global Pembrolizumab Sales by Country (2021-2026)
  5. 7.3.2 Global Pembrolizumab Sales by Country (2027-2032)
  6. 7.4 Global Pembrolizumab Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pembrolizumab Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pembrolizumab Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pembrolizumab Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pembrolizumab Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pembrolizumab Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pembrolizumab Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pembrolizumab Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pembrolizumab Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pembrolizumab Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pembrolizumab Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pembrolizumab Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pembrolizumab Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pembrolizumab Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pembrolizumab Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pembrolizumab Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pembrolizumab Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pembrolizumab Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pembrolizumab Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pembrolizumab Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pembrolizumab Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pembrolizumab Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pembrolizumab Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pembrolizumab Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pembrolizumab Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pembrolizumab Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pembrolizumab Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pembrolizumab Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pembrolizumab Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pembrolizumab Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pembrolizumab Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pembrolizumab Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pembrolizumab Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pembrolizumab Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Pembrolizumab Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Pembrolizumab Product Portfolio
  6. 8.1.5 Merck Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pembrolizumab Value Chain Analysis
  2. 9.1.1 Pembrolizumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pembrolizumab Sales Mode & Process
  6. 9.2 Pembrolizumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pembrolizumab Distributors
  9. 9.2.3 Pembrolizumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst